PT  - JOURNAL ARTICLE
AU  - Gao, Xin
AU  - Zhao, Chen
AU  - Yang, Junting
AU  - Yang, Ziming
AU  - Feng, Jingnan
AU  - Zhan, Siyan
AU  - Fan, Dongsheng
AU  - Liu, Zhike
TI  - Impact of the COVID-19 pandemic and vaccination on global, regional, and national burden of Guillain-Barre syndrome: observational study
AID  - 10.1101/2024.07.09.24309613
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.09.24309613
4099  - http://medrxiv.org/content/early/2024/07/10/2024.07.09.24309613.short
4100  - http://medrxiv.org/content/early/2024/07/10/2024.07.09.24309613.full
AB  - Objectives: To estimate the global, regional, and national burden and trends of Guillain-Barre Syndrome (GBS), and to explore the impact of the COVID-19 pandemic and related public health measures on the GBS burden. Design: Observational study. Setting: 204 countries and territories. Data sources: Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 and Our World in Data. Main outcome measures: All-cause and COVID-19-specific age-standardized years lived with disability (YLD) rates and estimated annual percentage change (EAPC). Results: Globally, the burden of GBS significantly increased during the COVID-19 pandemic, age-standardized YLD rates were 0.86 (95% uncertainty interval (UI): 0.56 to 1.24) per 100,000 people in 2020, rising to 1.75 (95% UI: 1.12 to 2.54) per 100,000 people in 2021, reflecting an EAPC of 70.35% (95% UI: 38.73 to 109.06) from 2019 to 2021. Regionally, the highest age-standardized YLD rates in 2020 and 2021 were observed in the high-income Asia Pacific and central Latin America, respectively, while the lowest rates were found in East Asia for both years. Age-standardized YLD rates rose 3.7 times faster in countries with a low socio-demographic index (SDI) versus countries with a high SDI (103.21% per year (95% UI: 71.10 to 141.35%) vs 28.02% per year (11.46 to 47.03)). Males generally had higher YLD rates across all age groups, with the highest disparity in those aged 80 and above. During the first two years of the pandemic, the increase in YLD rates was more pronounced in females and younger populations aged 15-29 years. A statistically negative correlation was observed between COVID-19 vaccination coverage and the GBS burden, with increases in full vaccination coverage per 100 people leading to decreases in all-cause YLD rates by 0.0070 and COVID-19-specific YLD rates by 0.0128 per 100,000 people. Conclusion: Predominantly driven by the surge of COVID-19 cases, the burden of GBS significantly increased during the first two years of the pandemic, especially in those countries with lower SDI levels. Greater increases in the GBS burden were observed in females and younger populations (15-29 years). Importantly, the benefits of vaccination outweighed the risks in controlling the post-COVID-19 GBS burden, although significant disparities in vaccination coverage existed between countries. These findings offer robust evidence facilitating public education and transparent communication on COVID-19 vaccination and highlight the urgency for targeted control measures to manage the burden of post-infection complications, such as GBS, during future COVID-19 waves or other potential pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation (Grant No. GZC20240064), Young Scientists Fund of the National Natural Science Foundation of China (Grant No. 82204175), Key Program of the National Natural Science Foundation of China (Grant No. 82330107), National Natural Science Foundation of China (Grant No. 81873784 and 82071426), Funds for International Cooperation and Exchange of the National Natural Science Foundation of China (Grant No. 7231101396), Bill and Melinda Gates Foundation (Grant No. INV-035024), and Clinical Cohort Construction Program of Peking University Third Hospital (Grant No. BYSYDL2019002 and BYSYZD2021004). The funders of this study had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the article for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Global Burden of Disease (GBD) study adhered to the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement 22 and obtained ethical clearance from the Institutional Review Board of the University of Washington (study 9060). Our World in Data (OWID) used publicly available data from reliable sources, including the World Health Organization (WHO), the National Ministry of Health, and the Centers for Disease Control and Prevention (CDC). Secondary analysis of the de-identified data from GBD and OWID did not require additional ethical approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe Global Burden of Disease (GBD) study is a comprehensive regional and global research program that assesses mortality and disability from major diseases, injuries, and risk factors. Our World in Data is an online publication that presents empirical research and data on global development issues. https://vizhub.healthdata.org/gbd-results/https://ourworldindata.org/